Cargando…

Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer

BACKGROUND: The 2007 St Gallen international expert consensus statement describes three risk categories and provides recommendations for treatment of early breast cancer. The set of recommendations on how to best treat primary breast cancer is recognized and used by clinicians worldwide. We now exam...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bauer, Katrina, Parise, Carol, Caggiano, Vincent
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886044/ https://www.ncbi.nlm.nih.gov/pubmed/20492696 http://dx.doi.org/10.1186/1471-2407-10-228

Ejemplares similares

The Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes
por: Parise, Carol A., et al.
Publicado: (2015)

Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers
por: Parise, Carol A., et al.
Publicado: (2014)

Prognostic significance of Ki67 in Chinese women diagnosed with ER(+)/HER2(−) breast cancers by the 2015 St. Gallen consensus classification
por: Hu, Yue, et al.
Publicado: (2017)

St.Gallen consensus on safe implementation of transanal total mesorectal excision
por: Adamina, Michel, et al.
Publicado: (2017)

Primary therapy of early breast cancer: Egyptian view of 2021 St. Gallen consensus
por: Khaled, Hussein, et al.
Publicado: (2022)

Controversial Opinion of “All pCRs are the Same” in St. Gallen International Consensus Guidelines 2021
por: Cong, Bin-Bin, et al.
Publicado: (2022)

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
por: Goldhirsch, A., et al.
Publicado: (2011)

Customizing early breast cancer therapies – The 2021 St. Gallen International Breast Cancer Consensus Conference()
por: Gnant, Michael, et al.
Publicado: (2022)

The 14th European Colorectal Congress (#ECCStGallen), 29 November–2 December 2020, St. Gallen, Switzerland
por: Adamina, M., et al.
Publicado: (2021)

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
por: Goldhirsch, A., et al.
Publicado: (2009)

The 13th European Colorectal Congress (#ECCStGallen), 1–5 December 2019, St Gallen, Switzerland: Congress Report
por: Adamina, M., et al.
Publicado: (2020)

Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference
por: Untch, Michael, et al.
Publicado: (2021)

Differences in Clinical Outcomes between Luminal A and B Type Breast Cancers according to the St. Gallen Consensus 2013
por: Ahn, Hyo Jung, et al.
Publicado: (2015)

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
por: Gillessen, S., et al.
Publicado: (2015)

St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer
por: Thomssen, Christoph, et al.
Publicado: (2021)

Abstracts presented at the 14th European Colorectal Congress (#ECCStGallen), 29.11.2020–2.12.2020, St.Gallen, Switzerland
por: Adamina, Michel, et al.
Publicado: (2021)

Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
por: Hu, Taobo, et al.
Publicado: (2021)

Comparison of 21-gene assay and St.Gallen International Expert Consensus in the treatment decision for patients with early invasive breast cancers
por: Luo, Ming, et al.
Publicado: (2019)

St Gallen molecular subtypes in screening‐detected and symptomatic breast cancer in a prospective cohort with long‐term follow‐up
por: Falck, A. K., et al.
Publicado: (2016)

BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma
por: Kumar, Mohit, et al.
Publicado: (2017)

Application of St Gallen Categories in Predicting Survival for Patients With Breast Cancer in Vietnam
por: Nguyen, Van Chu, et al.
Publicado: (2019)

Breast Cancer Mortality among Asian-American Women in California: Variation according to Ethnicity and Tumor Subtype
por: Parise, Carol, et al.
Publicado: (2016)

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
por: Goldhirsch, A., et al.
Publicado: (2013)

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
por: Coates, A. S., et al.
Publicado: (2015)

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
por: Burstein, H.J., et al.
Publicado: (2021)

Treatment of Early Breast Cancer: The 18th St. Gallen International Breast Cancer Consensus Conference against the Background of Current German Treatment Recommendations
por: Untch, Michael, et al.
Publicado: (2023)

Validity of St Gallen risk categories in prognostication of breast cancer patients in Southern Sri Lanka
por: Peiris, Harshini, et al.
Publicado: (2018)

Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study
por: Gómez-Acebo, Inés, et al.
Publicado: (2021)

St Gallen 2019 guidelines understage the axilla in lobular breast cancer: a population-based study
por: Narbe, U, et al.
Publicado: (2021)

Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019)
por: Untch, Michael, et al.
Publicado: (2019)

Highlights of the 17th St Gallen International Breast Cancer Conference 2021: customising local and systemic therapies
por: Reinert, Tomás, et al.
Publicado: (2021)

A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
por: Xie, Peiling, et al.
Publicado: (2021)

It is time for consensus on ‘consensus statements’
por: Blazey, Paul, et al.
Publicado: (2022)

Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis
por: Jung, Jaehag, et al.
Publicado: (2017)

ODP539 AIPB is a Biomarker for ER+/PR+/Her2- Breast Cancers
por: Cubbedge, Chandler, et al.
Publicado: (2022)

A retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana
por: Seshie, Bernard, et al.
Publicado: (2015)

A Mathematical Model to Predict Diagnostic Periods for Secondary Distant Metastases in Patients with ER/PR/HER2/Ki-67 Subtypes of Breast Cancer
por: Tyuryumina, Ella Ya., et al.
Publicado: (2020)

Financial Statements for the Year 2007
Publicado: (2008)

3D Visualization of the Dynamic Bidirectional Talk Between ER/PR and Her2 Pathways
por: Lyv, Jiahong, et al.
Publicado: (2021)

Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
por: Jiaxin, Chen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_salbc5eiku5hg2sqck62a2nr8p